Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Cash & Equivalents (2024 - 2025)

Historic Cash & Equivalents for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $58.2 million.

  • Prelude Therapeutics' Cash & Equivalents rose 28344.97% to $58.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.2 million, marking a year-over-year increase of 28344.97%. This contributed to the annual value of $16.5 million for FY2024, which is N/A changed from last year.
  • Prelude Therapeutics' Cash & Equivalents amounted to $58.2 million in Q3 2025, which was up 28344.97% from $77.3 million recorded in Q2 2025.
  • Over the past 5 years, Prelude Therapeutics' Cash & Equivalents peaked at $103.1 million during Q1 2025, and registered a low of $15.2 million during Q3 2024.